Improved transposons could cut cell therapy production costs says EMBL

By Gareth Macdonald contact

- Last updated on GMT

EMBL: new transposons could cut cell therapy production cost
EMBL: new transposons could cut cell therapy production cost

Related tags: Dna, Gene

EMBL researchers have developed variants of the “sleeping beauty” transposon they claim are more effective at inserting genetic material into cells.

The development – detailed in a study in Nature Communications​ – has implications for the production of cell therapies for leukaemia and lymphoma according to lead researcher, Dr Orsolya Barabas.

She told us the new versions of the transposon “create 30% more cells carrying the intended gene insertion. In principle, this means that with our new variants it should be quicker to engineer enough of a patients’ own T-cells to re-implant.​”

Transposons – also known as jumping genes – are sections of DNA sequence that can change position in the genome. Synthetic transposons – like Sleeping Beauty – can be used to deliver a desired gene into a cell.

Cheaper genetic manipulation

Using transposons to modify cell lines has a number of potential advantages over viral vector-based delivery technology, including lower production cost as Barabas explained.

Using transposons to engineer genomes for therapeutic applications is fundamentally cheaper than the current approaches that use viral gene delivery vehicles.

This is because using transposon tools only requires two pieces of specifically designed DNA, while for the viral delivery clinical-grade viral particles carrying the appropriate cargo have to be prepared, which is expensive.

She added that: “By some estimates, production of non-viral reagents such as transposons may cost one-tenth that of GMP-grade virus​.”

Barabas also expects the European Molecular Biology Laboratory's (EMBL's) Sleeping Beauty variants to reduce cell therapy production costs by cutting culturing times, although it is too early to estimate how much developers could save.

Source: Nature Communications

Title: “Sleeping Beauty transposase structure allows rational design of hyperactive variants for genetic engineering”

Authors Franka Voigt, Lisa Wiedemann, Cecilia Zuliani, Irma Querques, Attila Sebe, Lajos Mátés, Zsuzsanna Izsvák, Zoltán Ivics, Orsolya Barabas


Related topics: Bio Developments, Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us


View more